Evidence for including lutein and zeaxanthin in oral supplements for age-related macular degeneration

Affiliations

Editorial

David C Musch. JAMA Ophthalmol. 2014 Feb.

. 2014 Feb;132(2):139-41.

doi: 10.1001/jamaophthalmol.2013.7443.

¹ Departments of Ophthalmology and Visual Sciences and Epidemiology, University of Michigan, Ann Arbor.

No abstract available

Comment in

Experimental design issue for assessment of carotenoids lutein and zeaxanthin in age-related eye disease study 2 formulation for age-related macular degeneration.
Benke KK, Benke KE. Benke KK, et al. JAMA Ophthalmol. 2014 Jul;132(7):904. doi: 10.1001/jamaophthalmol.2014.1768. JAMA Ophthalmol. 2014. PMID: 25010177 No abstract available.
Making sense of the evidence from the age-related eye disease study 2 randomized clinical trial.
Downie LE, Keller PR. Downie LE, et al. JAMA Ophthalmol. 2014 Aug;132(8):1031. doi: 10.1001/jamaophthalmol.2014.2007. JAMA Ophthalmol. 2014. PMID: 25124957 No abstract available.
Making sense of the evidence from the age-related eye disease study 2 randomized clinical trial-reply.
Chew EY, Clemons TE. Chew EY, et al. JAMA Ophthalmol. 2014 Aug;132(8):1031-2. doi: 10.1001/jamaophthalmol.2014.2009. JAMA Ophthalmol. 2014. PMID: 25124958 No abstract available.

Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
Age-Related Eye Disease Study 2 (AREDS2) Research Group; Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3rd, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD. Age-Related Eye Disease Study 2 (AREDS2) Research Group, et al. JAMA Ophthalmol. 2014 Feb;132(2):142-9. doi: 10.1001/jamaophthalmol.2013.7376. JAMA Ophthalmol. 2014. PMID: 24310343 Free PMC article. Clinical Trial.